The Latest and Greatest New Biomarkers
Author:
- James A. de LemosJLJames A. de Lemos
- 11 December 2006
- journal article
- editorial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 166 (22) , 2428-2430
Abstract
In recent years, numerous new biomarkers have been proposed for risk stratification in coronary heart disease (CHD), as opportunistic researchers have capitalized on stored blood samples from large clinical trials and registries to perform rapid and relatively inexpensive biomarker screening. A number of biomarkers reflecting distinct pathophysiological processes, including C-reactive protein (CRP), B-type natriuretic peptide (BNP), and markers of renal function such as creatinine clearance (CrCl) and cystatin C, have been shown to provide independent prognostic value to traditional risk predictors in multivariable analyses. While the demonstrations of such associations are necessary first steps, they do not establish the full clinical utility of a biomarker, which is a more demanding process that requires validation in multiple cohorts, a reliable and cost-effective assay, and clear demonstration of incremental prognostic value over traditional risk models. An important but often overlooked consideration is that the biomarker must offer tangible value to the end users (the clinician and the patient) in order to be widely adopted. This is best accomplished by either improving diagnostic performance or providing therapeutic guidance. It is also possible that more accurate risk stratification may help to convince patients to comply with lifestyle recommendations and preventive therapies, although this has yet to be proven. Examples of biomarkers that have been widely adopted and largely meet the needs of clinicians and their patients include troponin testing for the diagnosis of myocardial infarction and low-density lipoprotein cholesterol measurement to guide lipid management.Keywords
This publication has 15 references indexed in Scilit:
- Comparison of N-Terminal Pro–B-Natriuretic Peptide, C-Reactive Protein, and Creatinine Clearance for Prognosis in Patients With Known Coronary Heart DiseaseArchives of internal medicine (1960), 2006
- Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor TrialCirculation, 2006
- Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) StudyCirculation, 2006
- The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for WomenAnnals of Internal Medicine, 2006
- Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular DiseaseAnnals of Internal Medicine, 2006
- N-Terminal Pro–B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart DiseaseNew England Journal of Medicine, 2005
- Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene studyEuropean Heart Journal, 2004
- N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy circulationACC Current Journal Review, 2003
- B-type natriuretic peptide in cardiovascular diseaseThe Lancet, 2003
- The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2001